This study will enroll 10,000 patients with obesity, with the participation of approximately 50 medical institutions nationwide. At baseline, demographic data, physical examinations, multiple laboratory tests (including complete blood count, urinalysis, liver/renal function, electrolytes, thyroid function panel \[3 items\], urine albumin/creatinine ratio, fasting glucose, fasting C-peptide, fasting insulin, HbA1c, blood lipids, etc.) and hepatic elasticity ultrasound will be performed. Patients will receive weight-loss therapy in routine clinical practice. Data on clinic visits, adverse events, and changes in therapeutic regimens will be centrally collected by investigators or their authorized representatives at Week 26 and Week 52.
This is a prospective, multicenter registry study designed to investigate the clinical characteristics and prognosis of obese patients in China, which may provide insights and opportunities to narrow the gaps in obesity-related clinical practice and improve clinical practice standards in China. The study will recruit 10,000 subjects from weight management clinics or endocrinology departments of 50 tertiary or higher-level medical institutions nationwide and follow them up for one year. Researchers will obtain informed consent for study participation from obese patients during routine clinical visits, after which patients will be enrolled and registered. Subsequently, subjects will undergo a baseline visit and be invited to participate in this 1 year observational registry study. They will receive clinical evaluations and the treatment regimens prescribed by their treating physicians. Following the scheduled baseline visit, subjects will continue to be followed up for 1 year through routine clinical care as part of this observational study, and all collected data will be uploaded to the registry center.
Study Type
OBSERVATIONAL
Enrollment
10,000
Chinese PLA General Hospital
Haidian, Being, China
The treatment model for overweight and obese individuals in China at present.
Time frame: 1 year
Observe the changes in liver fat content and liver stiffness in Chinese overweight and obese patients after 6 months and 12 months of follow-up: Liver stiffness measurement (LSM) and control attenuation index (Cap)
Time frame: 6 months and 12 months
Observe the changes in body weight after 6 months and 12 months of follow-up: BMI
Time frame: 6 months and 12 months
Evaluation of risk factors related to fatty liver disease in obesity combined with metabolic dysfunction
Time frame: 6 months and 12 months
Observe the changes in related metabolic indicators over 6 months and 12 months, including changes in indicators such as blood lipids, blood pressure, and blood sugar.
Time frame: 6 months and 12 months
Conduct a subset analysis for patients undergoing weight loss treatment with Mazdutide, analyzing related indicators including weight, metabolic indicators, cardiovascular and renal outcomes, and adverse reactions.
Time frame: 6 months and 12 months
Observe the social demographic and clinical characteristics of obese and overweight patients
1. Describe different social demographic characteristics (age, gender, race, education level, marital status, family history, physical activity, smoking history, alcohol consumption. 2. Describe different clinical characteristics (body mass index \[BMI\], body fat percentage, waist circumference, waist-to-hip ratio, waist-to-height ratio, duration of obesity, duration of fatty liver disease, the number, type, and prevalence of other obesity-related comorbidities: especially non-alcoholic fatty liver disease, polycystic ovary syndrome, sleep apnea syndrome, etc.) 3. Compare the differences in demographic and clinical characteristics among different groups of patients with different regions, different degrees of obesity, etc.
Time frame: 6 months and 12 months
Observe the impact of different weight management methods on cardiovascular and renal outcomes and their risk factors.
1. Observe the changes in weight-related indicators and metabolic-related 2. Compare the differences in cardiovascular and renal outcomes among different populations.
Time frame: 6 months and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.